Here’s what you should know:
1. The FDA is attempting to ensure every drug has at least three versions available on the market to combat price gouging.
2. The FDA released a list of more than 200 drugs it believes could have their prices hiked. Mr. Maris wrote in a research note that “no company in our coverage universe is more exposed to this new FDA effort than Valeant,” CNBC reports.
3. Mr. Maris believes companies will be able to create generics of several Valeant products.
4. The products on the list accounted for $713 million of Valeant’s $9.67 billion in 2016 revenues.
More articles on gastroenterology:
Synthetic Biologics receives Patent office allowance for active agent in IBS-C treatment — 3 key notes
GI center to know: Gastroenterology of the Rockies
Exact Sciences partners with pro-golfer & more — 6 GI company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
